Appukkuttan S, Farej R, Miles L, Purser M, Wen L. Budget-impact of adding darolutamide to a United States payer formulary for non-metastatic castration-resistant prostate cancer. Poster presented at the 2020 AMCP (Conference cancelled); April 21, 2020. Houston, TX. [abstract] J Manag Care Pharm. 2020 Apr 20; 26(4-a):S18.